Ainos (AIMD) Q3 2024 earnings summary

Executive summary

• Focused on point-of-care testing (POCT), VELDONA therapeutics, and synthetic RNA-driven medicine, with a pipeline including commercial-stage pet supplements and clinical-stage human/animal drugs.

• Ceased COVID-19 test kit sales in Q1 2024; now generating revenue from VELDONA Pet supplements in Taiwan.

• Advancing clinical studies for VELDONA human drugs and VOC POCT products, including Ainos Flora for female health.

• Licensed additional patents from TCNT to strengthen AI Nose and POCT technologies.

Financial highlights

• Q3 2024 revenue was nil, down from $24,489 in Q3 2023, due to the end of COVID-19 test kit sales.

• Net loss for Q3 2024 was $3,699,317, a 24% increase year-over-year; nine-month net loss was $10,209,149, up 30%.

• Operating expenses rose 16% in Q3 2024 and 25% for the nine months, driven by higher R&D and SG&A costs.

• Cash and cash equivalents at September 30, 2024 were $5,156,606, up from $1,885,628 at year-end 2023.

• Gross loss for the nine months was $31,945, down from $142,330 year-over-year, reflecting lower sales and cost of revenue.

Outlook and guidance

• Expects continued R&D spending to advance VOC POCT and VELDONA drug candidates, with increased clinical trial activity.

• Anticipates cash reserves, business revenues, and potential debt financing to fund operations over the next twelve months.

• May seek additional capital through equity or debt if needed; profitability not assured.